(275 days)
Not Found
No
The description details a standard immunoassay technique and data processing based on calibration curves, with no mention of AI or ML algorithms.
No.
The device is an in vitro diagnostic immunoassay that quantifies free thyroxine (FT4) to aid in the clinical assessment of thyroid status, but it does not directly treat or prevent a disease.
Yes.
The device is intended for the quantitative determination of free thyroxine (FT4) in human serum and is used as an aid in the clinical assessment of thyroid status, which are diagnostic purposes. The control samples are also used to monitor the accuracy and precision of the assay.
No
The device is an in vitro diagnostic immunoassay kit that relies on chemical reactions and a physical analyzer (LIAISON® Analyzer) to determine results. It is not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the DiaSorin LIAISON® FT4 assay is an in vitro chemiluminescent immunoassay intended for the quantitative determination of free thyroxine (FT4) in human serum. This directly aligns with the definition of an in vitro diagnostic device, which is used to examine specimens derived from the human body to provide information for diagnostic purposes.
- Device Description: The description details a laboratory-based assay method (chemiluminescent immunoassay) performed on a specific analyzer (LIAISON® Analyzer) using biological samples (human serum).
- Performance Studies: The performance studies described (Method Comparison, Reference Range/Expected Values, Reproducibility/Precision, Dilution Linearity, LoB/LoD/LoQ, Interfering Substances, Specificity) are typical studies conducted to validate the performance of an in vitro diagnostic assay.
- Predicate Device(s): The mention of predicate devices (Roche Elecsys® FT4 and Elecsys® PreciControl Universal) which are known IVD devices further supports that this device falls into the same category.
The DiaSorin LIAISON® FT4 assay is designed to be used outside of the body (in vitro) to analyze a human specimen (serum) to provide information about a person's thyroid status, which is a diagnostic purpose.
N/A
Intended Use / Indications for Use
The DiaSorin LIAISON® FT4 assay is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of free thyroxine (FT4) in human serum using the LIAISON® Analyzer. It is intended for use as aid in the clinical assessment of thyroid status.
The DiaSorin LIAISON® Control Thyroid 1, LIAISON® Control Thyroid 2 and LIAISON® Control Thyroid 3 are intended for use as assayed quality control samples to monitor the accuracy and precision of the DiaSorin LIAISON® FT4 assay.
Product codes (comma separated list FDA assigned to the subject device)
CEC, JJX
Device Description
The LIAISON® FT4 assay's method for quantitative determination of FT4 is based on the Solid Phase Antigen Linked Technique (SPALT) principle. A T4-protein-conjugate is coated on the magnetic particles (solid phase); a monoclonal antibody is linked to an isoluminol derivative (isoluminol-antibody conjugate). All assay steps and incubations are performed by the LIAISON® Analyzer.
Results are determined by a 2 point calibration conversion of the master curve to a working curve. The light signal, and hence the amount of isoluminol-antibody conjugate, is measured by a photomultiplier as relative light units (RLU) and is inversely related to FT4 concentration present in calibrators, patient samples or controls.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Human serum
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Method Comparison: A total of 201 samples were tested by the LIAISON® FT4 assay and a commercially available immunoassay. The method comparison study was performed according to CLSI EP9-A2 guideline.
Passing & Bablok regression analysis was performed on the results across the range of LIAISON® FT4 assay yielding agreement of y =1.0707x - 0.1211, R2 = 0.9633. The 95% confidence intervals for the slope were 1.03 to 1.09 and 95% confidence intervals for the intercept were -0.17 to -0.08 ng/dL.
Reference Range/Expected Values: Human serum samples from 130 apparently healthy adults were tested to determine the reference range for the LIAISON® FT4 assay.
Serum (130): Median 1.08 ng/dL (13.9 pmol/L). Observed 95% Normal Range 0.69 – 1.59 ng/dL (8.93 - 20.4 pmol/L).
Reproducibility/Precision:
20 Day Study Design: A twenty day reproducibility/precision study was performed at DiaSorin Inc. A coded panel comprised of 4 frozen serum samples was prepared by DiaSorin. The LIAISON® Control Thyroid (3 levels) were also tested in the study. The CLSI document EP5-A2 was consultred in the preparation of the testing protocol. The precision panel samples and kit controls were tested on one lot of LIAISON® FT4 assay in two replicates per run, 2 runs per day for 20 operating days for a total of 80 replicate results per sample. The mean, standard deviation, and coefficient of variation (%CV) of the results were computed for each of the tested samples.
Results: Kit Control 1: Mean 1.02, SD 0.08, %CV 7.9%. Kit Control 2: Mean 3.18, SD 0.22, %CV 6.9%. Kit Control 3: Mean 6.59, SD 0.46, %CV 7.0%. Sample 1: Mean 1.19, SD 0.09, %CV 8.0%. Sample 2: Mean 1.90, SD 0.14, %CV 7.5%. Sample 3: Mean 5.56, SD 0.40, %CV 7.1%. Sample 4: Mean 5.72, SD 0.40, %CV 7.1%.
5 Day Study Design: An additional five day precision study was performed at DiaSorin. The sample panel consisted of three frozen serum samples prepared by DiaSorin with FT4 concentrations near medical decision points. The precision panel samples were tested on one lot of LIAISON® FT4 assay in twelve replicates per run, one run per day for 5 operating days for a total of 60 replicate results per sample.
Results: Sample 1 (hypo): Mean 0.851, Total SD 0.08, Total %CV 9.5%. Sample 2 (normal): Mean 1.57, Total SD 0.13, Total %CV 8.6%. Sample 3 (hyper): Mean 3.25, Total SD 0.24, Total %CV 7.5%.
Dilution Linearity: An aliquot of a buffer sample containing phosphate buffered saline (PBS), 5% BSA was spiked with T4 and diluted with the same buffer. This yielded a sample with T4 levels spanning the measuring range of the LIAISON® FT4 assay (0.29 - 7.7 ng/dL). The sample was analyzed by the LIAISON® FT4 assay following CLSI EP6-A. The sample was diluted into ten evenly spaced intervals including the neat sample and tested in four replicates for each dilution on the LIAISON® Analyzer.
Results: The results were analyzed by a linear regression of measured FT4 concentration versus expected FT4. LIAISON® FT4 Assay is linear across the measuring range of the assay (0.29 - 7.7 ng/dL).
Traceability, Stability, Target Values:
Traceability: The LIAISON® FT4 kit calibrators are referenced to an 'in-house'' Primary Reference Standard preparation.
Calibrator Value Assignment: Calibrator concentrations are assigned through an internal procedure. Master standards are prepared from intermediate stock solutions. Concentrations are assigned by testing in 10 different assays against the Primary Reference Standard. The master calibrators are then used to assign values to the kit calibrators using multiple LIAISON® analyzers with several kits calibrators over several runs to determine the target values.
Calibrator Stability: Reagent integral is stable until the expiration date printed on the label when stored as directed and for 2 weeks (14 days) on board the LIAISON® analyzer or opened and stored at 2-8°C. Calibration curve stability was performed and demonstrated that kit performance was acceptable to 2 weeks from calibration.
Control Value Assignment: A minimum of 60 valid test results for each control are used in the range assignment. The LIAISON® Control Thyroid 1, LIAISON® Control Thyroid 2, LIAISON® Control Thyroid 3 are tested on a minimum of 3 LIAISON® Analyzers, using 2 different approved LIAISON® FT4 assay kit lots, at a minimal time period of 3 days. The mean value and the standard deviation (std) is calculated from the test results. The target value of the controls is given by the calculated mean value. The target range is given by the mean value +/- 3 std.
Control Stability: Lyophilized controls are stable until the expiration date shown on the product labeling when stored as instructed. Reconstituted controls are stable for up to 48 hours when stored at 2-8°C. For longer storage periods, control aliquots should be frozen to -20°C.
LoB/LoD/LoQ: Determined according to CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation.
Limit of Blank: ≤ 0.06 nq/dL. Limit of Detection: 0.13 na/dL. Limit of Quantitation: 0.29 ng/dL.
Interfering Substances: Controlled studies of potentially interfering substances showed no interference at the concentration for each substance listed in the LIAISON® FT4 assay. The testing was based on CLSI-EP7-A2.
Specificity: The cross-reactivity of the LIAISON®FT4 assay with substances has been expressed as the ratio of the amount of T4 required to displace 50% of the maximally bound labeled T4 from the anti-T4 antibody, to the amount of the cross-reactant to give the same 50% displacement. Amounts for cross-reactant and analyte are taken from the displacement curve. The ratio of the two amounts as percentage-value is the % cross-reactivity of the cross reactant.
Cross-Reactant % Cross-reactivity: D-T4 100%, 3-iodo-L-Tyrosine 0%, 3,5-diiodo-L-Tyrosine 0%, 3,3',5,5'-tetra-iodothyroacetic acid 0%.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found. Key metrics from performance studies were R2, confidence intervals for slope and intercept for method comparison, mean, SD, %CV for reproducibility/precision, LoB, LoD, LoQ, and % cross-reactivity for specificity.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1695 Free thyroxine test system.
(a)
Identification. A free thyroxine test system is a device intended to measure free (not protein bound) thyroxine (thyroid hormone) in serum or plasma. Levels of free thyroxine in plasma are thought to reflect the amount of thyroxine hormone available to the cells and may therefore determine the clinical metabolic status of thyroxine. Measurements obtained by this device are used in the diagnosis and treatment of thyroid diseases.(b)
Classification. Class II.
0
121951
5.0 510(k) SUMMARY
March 25, 2013
SUBMITTED BY:
Kelly R. Sauer Regulatory Affairs Specialist DiaSorin Inc. 1951 Northwestern Avenue P.O. Box 285 Stillwater, MN 55082-0285 Phone (651) 351-5884 Fax (651) 351-5669 Email: kelly.sauer@diasorin.com
· APR 4 2013
DATE PREPARED:
NAME OF DEVICE:
Trade Name:
LIAISON® FT4 LIAISON® Control Thyroid 1 LIAISON® Control Thyroid 2 LIAISON® Control Thyroid 3
Common Names/Descriptions:
Classification Names:
Free Thyroxine Assay
Free Thyroxine Test System: Class II 21 CFR 862.1695; Clinical Chemistry (75) Quality Control Material: Class I, reserved 21 CFR 862.1660; Clinical Chemistry (75)
Product Code:
PREDICATE DEVICE:
Roche Elecsys® FT4 Reference K961489 (assav) Elecsys® PreciControl Universal Reference K090541 (control set)
DEVICE DESCRIPTION:
INTENDED USE:
The DiaSorin LIAISON® FT4 assay is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of free thyroxine (FT4) in human serum using the LIAISON® Analyzer. It is intended for use as aid in the clinical assessment of thyroid status.
CEC. JJX
The DiaSorin LIAISON® Control Thyroid 1, LIAISON® Control Thyroid 2 and LIAISON® Control Thyroid 3 are intended for use as assayed quality control samples to monitor the accuracy and precision of the DiaSorin LIAISON® FT4 assay.
Section 5
1
KIT DESCRIPTION:
The LIAISON® FT4 assay's method for quantitative determination of FT4 is based on the Solid Phase Antigen Linked Technique (SPALT) principle. A T4-protein-conjugate is coated on the magnetic particles (solid phase); a monoclonal antibody is linked to an isoluminol derivative (isoluminol-antibody conjugate). All assay steps and incubations are performed by the LIAISON® Analyzer.
Results are determined by a 2 point calibration conversion of the master curve to a working curve. The light signal, and hence the amount of isoluminol-antibody conjugate, is measured by a photomultiplier as relative light units (RLU) and is inversely related to FT4 concentration present in calibrators, patient samples or controls.
COMPARISON TO PREDICATE DEVICE:
The DiaSorin LIAISON FT4 assay is substantially equivalent in principle and performance to the Roche Elecsys® FT4 Test (K961489) which was FDA cleared June 11, 1996.
| Table 1: Table of Assay Similarities and Differences | ||
|---|---|---|
| Characteristic | New Device | |
| LIAISON® FT4 | Predicate Device | |
| Roche Elecsys® FT4 (K961489) | ||
| Intended Use | The DiaSorin LIAISON® FT4 | |
| Assay is a chemiluminescent | ||
| immunoassay (CLIA) intended | ||
| for the quantitative | ||
| determination of free thyroxine | ||
| (FT4) in human serum using | ||
| the LIAISON® Analyzer. | Immunoassay for the in vitro | |
| quantitative determination of free | ||
| thyroxine in human serum and | ||
| plasma. The | ||
| electrochemiluminescence | ||
| Immunoassay "ECLIA" is | ||
| intended for use on Elecsys and | ||
| cobas e immunoassay | ||
| analyzers. | ||
| Indications for Use | For use as an aid in the | |
| clinical assessment of thyroid | ||
| status | Same | |
| Measured Analyte | Free thyroxine | Free thyroxine |
| Assay Type | Chemiluminescent | |
| Immunoassay | Electrochemiluminescent | |
| immunoassay | ||
| Calibration | Two-point verification of | |
| stored master curve. | Same | |
| Reagent Integral | ||
| Storage | On-board or in refrigerator@ | |
| 2-8°C | Same | |
| Sample | ||
| Handling/Processing | Automated | Same |
| Unit of Measure | ng/dL or pmol/L | Same |
| Reference range | Serum 0.69 - 1.59 ng/dL | |
| (8.93 -20.4 pmol/L) | Serum 0.93 - 1.70 ng/dL | |
| (12.0 - 21.9 pmol/L) | ||
| Measuring range | 0.29 - 7.7 ng/dL | |
| (3.73 - 99.1 pmol/L) | 0.023 - 7.77ng/dL | |
| (0.300 - 100.0 pmol/L) | ||
| Sample Matrix | Human serum | Human serum and plasma |
2
| Sample size | 50µL | 15µL |
|---|---|---|
| Conjugate Antibody | Mouse monoclonal | |
| anti-thyroxine | Sheep polyclonal anti-thyroxine | |
| Assay time | 17 minutes | 18 minutes |
| Open storage | ||
| 2-8°C | 2 weeks | 12 weeks |
| Open storage | ||
| on analyzer | 2 weeks | 4 weeks |
| Calibrators | 2 levels - Included in integral | 2 levels - Not included with kit |
| Controls | 3 levels | 2 levels |
DiaSorin LIAISON® Control Thyroid 1, LIAISON® Control Thyroid 2, LIAISON® Control Thyroid 3 and Elecsys® PreciControl Universal Similarities and Differences
| Table 2: Table of Control Similarities and Differences | ||
|---|---|---|
| Characteristic | New Device | |
| LIAISON® Control Thyroid 1 | ||
| LIAISON® Control Thyroid 2 | ||
| LIAISON® Control Thyroid 3 | Predicate Device | |
| Elecsys® PreciControl | ||
| Universal (K090541) | ||
| Intended Use | Intended for use as quality | |
| control samples to monitor the | ||
| accuracy and precision of the | ||
| DiaSorin LIAISON® FT4 assay | Intended for use as quality | |
| control of Elecsys® | ||
| immunoassays on the Elecsys® | ||
| and Cobas® e immunoassay | ||
| analyzers | ||
| Matrix | Human serum | Same |
| Reagent Format | Lyophilized | Same |
| Storage | Unopened store at 2-8° C until | |
| expiration date | Same | |
| Levels | Three concentrations : | |
| Low, medium, high | Two concentrations : | |
| Low and high | ||
| Reagent Format | 4 vials x 5.0 mL each level | |
| Each level provided separately | 2 vials x 3.0 ml each level | |
| Handling | Reconstitue with 5.0 mL | |
| distilled water | ||
| and allow to stand 15 minutes | ||
| before use | Reconstitute with 3.0 mL | |
| distilled water | ||
| and allow to stand 30 minutes | ||
| before use. | ||
| Open Storage | Reconstituted : | |
| 48 hours at 2-8° C | ||
| For longer storage periods, | ||
| frozen to -20 °C | Reconstituted : | |
| On analyzer at 20-25° C up to 5 | ||
| hrs ; 3 days at 2-8° C; | ||
| -20° C for up to 1 month |
:
3
PERFORMANCE DATA:
Method Comparison:
A total of 201 samples were tested by the LIAISON® FT4 assay and a commercially available immunoassay. The method comparison study was performed according to CLSI EP9-A2 guideline.
Passing & Bablok regression analysis was performed on the results across the range of LIAISON® FT4 assay yielding agreement of y =1.0707x - 0.1211, R2 = 0.9633. The 95% confidence intervals for the slope were 1.03 to 1.09 and 95% confidence intervals for the intercept were -0.17 to -0.08 ng/dL.
Reference Range/Expected Values:
Human serum samples from 130 apparently healthy adults were tested to determine the reference range for the LIAISON® FT4 assay.
| Apparently Healthy Adults | Median | Observed 95% Normal Range |
|---|---|---|
| Serum (130) | 1.08 ng/dL | 0.69 — 1.59 ng/dL |
| 13.9 pmol/L | 8.93 - 20.4 pmol/L | |
| Consider these limits as guidelines only. Each laboratory should establish its own reference range |
Reproducibility/Precision:
20 Day Study Design
A twenty day reproducibility/precision study was performed at DiaSorin Inc. A coded panel comprised of 4 frozen serum samples was prepared by DiaSorin. The LIAISON® Control Thyroid (3 levels) were also tested in the study. The CLSI document EP5-A2 was consultred in the preparation of the testing protocol.
The precision panel samples and kit controls were tested on one lot of LIAISON® FT4 assay in two replicates per run, 2 runs per day for 20 operating days for a total of 80 replicate results per sample.
The mean, standard deviation, and coefficient of variation (%CV) of the results were computed for each of the tested samples.
Results:
The 20 day results are summarized in Table 3 as sample overall mean FT4 concentration in ng/dL, computed SDs and %CVs for between run and total.
4
| Mean | Between Run | TOTAL | ||||
|---|---|---|---|---|---|---|
| Sample | N | (ng/dL) | SD | %CV | SD | %CV |
| Kit Control 1 | 80 | 1.02 | 0.02 | 1.8% | 0.08 | 7.9% |
| Kit Control 2 | 80 | 3.18 | 0.07 | 2.3% | 0.22 | 6.9% |
| Kit Control 3 | 80 | 6.59 | 0.33 | 4.9% | 0.46 | 7.0% |
| Sample 1 | 80 | 1.19 | 0.03 | 2.7% | 0.09 | 8.0% |
| Sample 2 | 80 | 1.90 | 0.05 | 2.4% | 0.14 | 7.5% |
| Sample 3 | 80 | 5.56 | 0.17 | 3.1% | 0.40 | 7.1% |
| Sample 4 | 80 | 5.72 | 0.17 | 2.9% | 0.40 | 7.1% |
Table 3: Reproducibility/Precision Results - 20 day
5 Day Study Design
An additional five day precision study was performed at DiaSorin. The sample panel consisted of three frozen serum samples prepared by DiaSorin with FT4 concentrations near medical decision points.
The precision panel samples were tested on one lot of LIAISON® FT4 assay in twelve replicates per run, one run per day for 5 operating days for a total of 60 replicate results per sample.
Results:
The 5 day results are summarized in Table 4 as sample overall mean FT4 concentration in ng/dL, computed SDs and %CVs for between run and total.
| Sample | N | Mean (ng/dL) | Between Run
SD | Between Run
%CV | TOTAL
SD | TOTAL
%CV |
|-------------------|----|--------------|-------------------|--------------------|-------------|--------------|
| Sample 1 (hypo) | 60 | 0.851 | 0.08 | 9.7 | 0.08 | 9.5% |
| Sample 2 (normal) | 60 | 1.57 | 0.14 | 9.0 | 0.13 | 8.6% |
| Sample 3 (hyper) | 60 | 3.25 | 0.24 | 7.4 | 0.24 | 7.5% |
Table 4: Reproducibility/Precision Results - 5 day
Dilution Linearity:
An aliquot of a buffer sample containing phosphate buffered saline (PBS), 5% BSA was spiked with T4 and diluted with the same buffer. This yielded a sample with T4 levels spanning the measuring range of the LIAISON® FT4 assay (0.29 - 7.7 ng/dL). The sample was analyzed by the LIAISON® FT4 assay following CLSI EP6-A. The sample was diluted into ten evenly spaced intervals including the neat sample and tested in four replicates for each dilution on the LIAISON® Analyzer.
Results:
The results were analyzed by a linear regression of measured FT4 concentration versus expected FT4. The resulting regression equation:
5
LIAISON® FT4 Assay is linear across the measuring range of the assay (0.29 - 7.7 ng/dL).
Traceability, Stability, Target Values:
Traceability: The LIAISON® FT4 kit calibrators are referenced to an 'in-house'' Primary Reference Standard preparation.
Calibrator Value Assignment: Calibrator concentrations are assigned through an internal procedure. Master standards are prepared from intermediate stock solutions. Concentrations are assigned by testing in 10 different assays against the Primary Reference Standard. The master calibrators are then used to assign values to the kit calibrators using multiple LIAISON® analyzers with several kits calibrators over several runs to determine the target values.
Calibrator Stability: Reagent integral is stable until the expiration date printed on the label when stored as directed and for 2 weeks (14 days) on board the LIAISON® analyzer or opened and stored at 2-8°C.
Calibration curve stability was performed and demonstrated that kit performance was acceptable to 2 weeks from calibration.
LIAISON® FT4 Calibrator 1 is manufactured to have a FT4 level between 0.45 - 0.55 ng/dL. LIAISON® FT4 Calibrator 2 is manufactured to have a FT4 level between 5.0 – 7.0 ng/dL.
Control Value Assignment: A minimum of 60 valid test results for each control are used in the range assignment. The LIAISON® Control Thyroid 1, LIAISON® Control Thyroid 2, LIAISON® Control Thyroid 3 are tested on a minimum of 3 LIAISON® Analyzers, using 2 different approved LIAISON® FT4 assay kit lots, at a minimal time period of 3 days. The mean value and the standard deviation (std) is calculated from the test results. The target value of the controls is given by the calculated mean value. The target range is given by the mean value +/- 3 std.
Control Stability: Lyophilized controls are stable until the expiration date shown on the product labeling when stored as instructed.
Reconstituted controls are stable for up to 48 hours when stored at 2-8°C. For longer storage periods, control aliquots should be frozen to -20°C.
LIAISON® Control Thyroid 1 has a target value of 1.0 ng/dL LIAISON® Control Thyroid 2 has a target value of 3.0 ng/dL LIAISON® Control Thyroid 3 has a target value of 6.0 ng/dL
6
LoB/LoD/LoQ
The Limit of Blank, Limit of Detection and Limit of Quantitation were determined according to CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation.
The following limits were determined with the LIAISON® FT4 assay:
Limit of Blank: ≤ 0.06 nq/dL Limit of Detection: 0.13 na/dL Limit of Quantitation: 0.29 ng/dL
Interfering Substances
Controlled studies of potentially interfering substances showed no interference at the concentration for each substance listed below in the LIAISON® FT4 assay. The testing was based on CLSI-EP7-A2.
| Substance/Drug | Concentration
Tested |
|----------------------------------------------------------|-------------------------|
| Hemoglobin | 1000 mg/dL |
| Triglycerides | 3000 mg/dL |
| Bilirubin (conj) | 20 mg/dL |
| Bilirubin (unconj) | 20 mg/dL |
| Salicylic acid | 741300 ng/dL |
| Acetylsalicylic acid | 907200 ng/dL |
| Phenylbutazone | 1540500 ng/dL |
| Diphenylhydantoin | 1301397 ng/dL |
| Amiodarone | 3396600 ng/dL |
| 8-Anilino-1-naphtalene
sulfonic acid
ammonium salt | 1579200 ng/dL |
| Furosemide | 1626000 ng/dL |
| Iopanic acid | 2842000 ng/dL |
| DL-propranolol | 1520000 ng/dL |
| Rheumatoid Factor | 54 IU/mL |
Specificity
The cross-reactivity of the LIAISON®FT4 assay with these substances has been expressed where possible as the ratio of:
- The amount of the T4 required to displace 50% of the maximally bound labeled T4 from . the anti-T4 antibody,
- The amount the cross-reactant to give the same 50% displacement. .
Amounts for cross-reactant and analyte are taken from the displacement curve. The ratio of the two amounts as percentage-value is the % cross-reactivity of the cross reactant.
7
| Cross-Reactant | % Cross-reactivity |
|---|---|
| D-T4 | 100% |
| 3-iodo-L-Tyrosine | 0% |
| 3,5-diiodo-L-Tyrosine | 0% |
| 3,3',5,5'-tetra-iodothyroacetic acid | 0% |
CONCLUSION:
The material submitted in this premarket notification is complete and supports the basis for substantial equivalence. The labeling is sufficient and satisfies the requirements of 21 CFR Part 809.10.
8
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/8/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the bird-like figure.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
April 4, 2013
KELLY R SAUER REGULATORY AFFAIRS SPECIALIST DIASORIN 1951 NORTHWESTERN AVE. P.O. BOX 285 STILLWATER MN 55082
Re: K121951
Trade/Device Name: LIAISON® FT4, LIAISON® Control Thyroid 1, LIAISON® Control Thyroid 2, LIAISON® Control Thyroid 3
Regulation Number: 21 CFR 862.1695 Regulation Name: Free thyroxine test system Regulatory Class: II Product Code: CEC, JJX Dated: March 25, 2013 Received: March 28, 2013
Dear Ms. Sauer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Ilisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements . as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
9
If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours.
Carol C. Benson -S for
Courtney H. Lias, Ph.D.
Director, Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
10
Indications for Use
510(k) Number (if known): K121951
Device Name: LIAISON® FT4 LIAISON® Control Thyroid 1, LIAISON® Control Thyroid 2 LIAISON® Control Thyroid 3
Indications for Use:
The DiaSorin LIAISON® FT4 assay is an in vitro chemiluminescent immunoassay intended for the quantitative determination of free thyroxine (FT4) in human serum using the LIAISON® Analyzer. It is intended for use as an aid in the clinical assessment of thyroid status.
The DiaSorin LIAISON® Control Thyroid 1, LIAISON® Control Thyroid 2 and LIAISON® Control Thyroid 3 are intended for use as assayed quality control samples to monitor the accuracy and precision of the DiaSorin LIAISON® FT4 assay
Prescription Use X (21 CFR Part 801 Subpart D) And/Or
Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)
YungW.DChan -S
Division Sign-Off Office of In Vitro Diagnostics and Radiological Health
510(k) K121951
Page 1 of 1